General
Preferred name
CLOFARABINE
Synonyms
Clofarex ()
Evoltra ()
Clolar ()
(2R,3R,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol ()
Clofarabine ()
Clofarabina ()
NSC-759857 ()
Ivozall ()
P&D ID
PD003455
CAS
123318-82-1
Tags
available
prodrug
drug
Approved by
FDA
EMA
First approval
2004
Drug indication
Acute lymphoblastic leukaemia
Leukemia
Myelodysplastic syndrome
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION A DNA polymerase (α/δ/ε) inhibitor, DNA and ribonucleoside-diphosphate reductase (RR1) inhibitor. (GtoPdb)
PRICE 39
DESCRIPTION inducer of DNA damage (Informer Set)
DESCRIPTION Selective inhibitor of MEK1/2 (Tocris Bioactive Compound Library)
DESCRIPTION Deoxycytidine kinase (dCK) substrate (Tocriscreen Plus)
DESCRIPTION Deoxycytidine kinase (dCK) substrate (Tocriscreen Total)
DESCRIPTION Clofarabine is metabolized intracellularly to the active 5'-monophosphate metabolite by deoxycytidine kinase and 5'-triphosphate metabolite by mono- and di-phospho-kinases. It is used for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic leukemia after at least two prior regimens. (Enamine Bioactive Compounds)
DESCRIPTION Clofarabine (Clofarex)m, a second generation purine nucleoside analog with antineoplastic activity, inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase. (TargetMol Bioactive Compound Library)
Cell lines
18
Organisms
1
Compound Sets
28
AdooQ Bioactive Compound Library
A10228
Cayman Chemical Bioactives
14125
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL1750
ChEMBL Drugs
CHEMBL1750
Concise Guide to Pharmacology 2017/18
6802
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00631
DrugBank Approved Drugs
DB00631
DrugCentral
691
DrugCentral Approved Drugs
691
DrugMAP
DMCVJ86
DrugMAP Approved Drugs
DMCVJ86
Enamine Bioactive Compounds
EBC-11026
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101535
Guide to Pharmacology
6802
Informer Set
660288
NCATS Inxight Approved Drugs
762RDY0Y2H
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
Clofarabine
TargetMol Bioactive Compound Library
T0297
Tocris Bioactive Compound Library
2600
Tocriscreen Plus
2600
Tocriscreen Total
External IDs
46
Properties
(calculated by RDKit )
Molecular Weight
303.05
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
3
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
-0.35
TPSA
119.31
Fraction CSP3
0.5
Chiral centers
4.0
Largest ring
6.0
QED
0.65
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Compound status
FDA
Target Type
Enzymes
MOA
ribonucleoside-diphosphate reductase inhibitor
Substrate
DNA Polymerase Inhibitors
Ribonucleoside-Diphosphate Reductase Inhibitors
Ribonucleotide Reductase inhibitor
Target
DNA
DNA polymerase (alpha/delta/epsilon)
Deoxycytidine kinase
Ribonucleoside-diphosphate reductase RR1
POLA1, POLD1, POLE, RRM1, RRM2, RRM2B
Apoptosis related,Autophagy,DNA/RNA Synthesis,RNR
Nucleoside antimetabolite/analog
RR
Primary Target
Other Kinases
Member status
member
Indication
acute lymphoblastic leukemia (ALL)
Pathway
Apoptosis
Autophagy
Cell Cycle/Checkpoint
DNA Damage/DNA Repair
Therapeutic Class
Anticancer Agents
Source data